The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

Cancer Prevention Research, published by the American Association for Cancer Research, is a leading journal dedicated to advancing our understanding of cancer prevention strategies and their implementation in public health. With an ISSN of 1940-6207 and E-ISSN 1940-6215, this journal serves as a pivotal platform for researchers, healthcare professionals, and students who are committed to unraveling the complexities of cancer etiology and preventive measures. Since its inception in 2008, the journal has carved a niche in the scientific community, achieving notable rankings including Q2 in Cancer Research and Q1 in both Medicine (miscellaneous) and Oncology, highlighting its significance in disseminating influential research. Cancer Prevention Research is indexed in Scopus, reflecting a robust impact factor, and features a range of articles that address the preventive aspects of cancer to promote healthier populations. With access options available, it invites contributions that bridge laboratory findings with epidemiologic insights, making it an essential resource for anyone dedicated to reducing the burden of cancer globally.

Cancer Epidemiology, published by ELSEVIER SCI LTD, serves as a premier platform for disseminating innovative research in the areas of cancer epidemiology and oncology. Operating from the Netherlands, this journal provides a critical insight into the factors influencing cancer incidence, including genetic, environmental, and lifestyle variables. With an impact factor reflecting its significance in the field, it holds a respectable Q2 ranking in Cancer Research, Epidemiology, and Oncology. The journal spans a wide range of topics and publishes studies that aim to bridge gaps in existing literature through rigorous research methodologies. Researchers and professionals interested in acquiring the latest insights and contributing to the evolving discourse on cancer epidemiology will find this journal an invaluable resource. Access to articles may be available through open access options, ensuring the widest dissemination of knowledge.

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

The Journal of Cancer Epidemiology, published by HINDAWI LTD, is a premier open access journal that has been disseminating vital research findings since 2008. With ISSN 1687-8558 and E-ISSN 1687-8566, this journal is dedicated to enhancing our understanding of cancer's epidemiological factors, thereby fostering advancements in public health, genetics, and environmental health. The journal's current quartile ranking places it in Q3 for Epidemiology and Public Health, as well as Q4 for Genetics, reflecting its growing influence in these fields. As of 2023, it holds respectable Scopus rankings, including a rank of #73 in Epidemiology, positioning it within the 51st percentile. Based in the United States with an address in London, this journal represents a crucial platform for researchers, professionals, and students eager to contribute to the global fight against cancer. For those passionate about uncovering insights into cancer risk factors and trends, the Journal of Cancer Epidemiology offers a comprehensive repository of high-quality research accessible to all.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

INDIAN JOURNAL OF CANCER, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of oncology, providing dedicated insight into cancer research and its clinical applications since its inception in 1965. With an ISSN of 0019-509X and an E-ISSN of 1998-4774, this esteemed journal facilitates the dissemination of knowledge related to cancer prevention, diagnosis, and treatment strategies within the Indian context and beyond. Although classified within the Q3 quartile of oncology journals and ranked #292 out of 404 in its category in the Scopus database, the INDIAN JOURNAL OF CANCER continues to play a vital role in advancing the dialogue around cancer management. This journal is particularly significant for researchers, professionals, and students intent on contributing to the evolving landscape of oncology, offering a platform for sharing innovative findings and fostering collaboration among the academic community. Located in Mumbai, India, the journal's commitment to impactful research is reflected in its ongoing efforts to bridge gaps in cancer knowledge and address the unique challenges faced within the region and globally.

Middle East Journal of Cancer, with an ISSN of 2008-6709 and an E-ISSN of 2008-6687, is a prominent open-access journal published by Shiraz University of Medical Sciences since 2010. Based in Iran, the journal aims to advance the knowledge and understanding of cancer research and oncology through the dissemination of high-quality, peer-reviewed articles. With open access availability, it promotes global collaboration and accessibility in research, making findings readily available to a wider audience. The journal is categorized in Q4 for both Cancer Research and Oncology as of 2023, highlighting its emerging presence in these fields. Alongside its Scopus ranks, where it positions 319th out of 404 in Medicine - Oncology and 198th out of 230 in Biochemistry, Genetics and Molecular Biology - Cancer Research, it serves as a platform for researchers, professionals, and students to enrich their expertise and contribute to the evolving landscape of cancer studies. The journal's continuous commitment to quality and accessibility represents an essential resource for those dedicated to advancing cancer research and improving patient outcomes in the Middle East and beyond.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.